University of Florida and Shands Children's Hospital, Gainesville, FL, USA.
Am J Transplant. 2011 Apr;11(4):751-8. doi: 10.1111/j.1600-6143.2011.03470.x.
Post-transplant lymphoproliferative disorder (PTLD) has been associated with high mortality, but recent anecdotal survival appeared better. From 1988 to 2010, the NAPRTCS registry had 235 registered PTLD cases. We sent a special 25-point questionnaire study to the NAPRTCS centers with the most recent 150 cases to obtain additional follow-up data not collected in the master registry, our objective being to determine the recent outcomes after PTLD and determine prognostic factors. We received 92 completed responses, in which only 12 (13%) deaths were reported, 2 from nonmedical causes, 10 with a functioning graft. Kaplan-Meier-calculated patient survival was 90.6% at 1 year and 87.4% at 3, 4 and 5 years post-PTLD. Graft survival post-PTLD was 81.8% at 1 year, 68.0% at 3 years and 65.0% at 5 years. Seven patients received a retransplant after PTLD, with no PTLD recurrence reported. Using all 235 PTLD cases, the covariates associated with better patient survival were more recent year of PTLD diagnosis (adjusted hazard ratio AHR 0.86, p < 0.001), and with worse survival were late PTLD (AHR 1.98, p = 0.0176) and patient age above 13 at PTLD (AHR 3.43, p value 0.022). In children with kidney transplants, patient survival has improved with more recent PTLDs.
移植后淋巴组织增生性疾病(PTLD)与高死亡率相关,但最近的传闻生存率似乎更好。1988 年至 2010 年,NAPRTCS 登记处有 235 例已登记的 PTLD 病例。我们向 NAPRTCS 中心发送了一份特别的 25 点问卷研究,其中包括最近的 150 例病例,以获取未在主登记处收集的额外随访数据,我们的目的是确定 PTLD 后的近期结果,并确定预后因素。我们收到了 92 份完整的答复,其中仅报告了 12 例(13%)死亡,其中 2 例死于非医疗原因,10 例移植肾功能正常。PTLD 后 1 年、3 年、4 年和 5 年的 Kaplan-Meier 计算的患者生存率分别为 90.6%、87.4%、87.4%和 87.4%。PTLD 后 1 年、3 年和 5 年的移植物存活率分别为 81.8%、68.0%和 65.0%。7 例患者在 PTLD 后接受了再次移植,未报告 PTLD 复发。使用所有 235 例 PTLD 病例,与更好的患者生存率相关的协变量是 PTLD 诊断的较近年(调整后的危险比 AHR 0.86,p <0.001),与生存率较差相关的是晚期 PTLD(AHR 1.98,p = 0.0176)和 PTLD 时年龄大于 13 岁(AHR 3.43,p 值 0.022)。在接受肾移植的儿童中,PTLD 较近的患者生存率有所提高。